Enzyme-Linked Immunosorbent Assay Testing Market Report 2024

This Enzyme-Linked Immunosorbent Assay Testing market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The enzyme-linked immunosorbent assay testing market size has grown strongly in recent years. It will grow from $2.68 billion in 2023 to $2.85 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed during the historic period can be attributed to several factors, including the prevalence of chronic diseases, increased funding and focus on biomedical research, approval of ELISA tests by regulatory bodies, government initiatives, and health awareness programs.

The enzyme-linked immunosorbent assay testing market size is expected to see strong growth in the next few years. It will grow to $3.65 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The anticipated growth during the forecast period can be attributed to several factors, including rising demand for personalized medicine, an increasing geriatric population, a greater emphasis on early detection, improved access to healthcare services, and a growing need for chronic disease monitoring. Key trends expected during this period include technological advancements, a rising demand for point-of-care testing, expanding application areas, the adoption of high-throughput screening, and the emergence of digital ELISA.

The increasing incidence of infectious disorders is expected to drive growth in the enzyme-linked immunosorbent assay (ELISA) testing market. Infectious disorders, caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, can spread between individuals and affect various body systems. The rise in these disorders is due to factors such as increased global travel and the growing issue of antimicrobial resistance, which complicates infection control efforts. ELISA testing is valuable for managing infectious disorders as it enables precise detection and quantification of specific antigens or antibodies associated with infections, aiding in diagnosis, monitoring disease progression, and assessing treatment effectiveness. For example, in February 2024, the World Health Organization, a Switzerland-based public health organization, reported that 58,114 cases of measles were recorded in the European Region in 2023, a significant increase from 941 cases in 2022. This rising incidence of infectious disorders is thus propelling the growth of the ELISA testing market.

Leading companies in the ELISA testing market are advancing their product offerings with innovations such as novel ELISA kits to enhance diagnostic accuracy and address diverse research and clinical requirements. These advanced ELISA kits offer improved accuracy, sensitivity, and usability for detecting and quantifying biomarkers. For instance, in February 2023, Charles River Laboratories, a US-based pharmaceutical firm, launched a novel ELISA kit designed for detecting and quantifying residual host cell proteins (HCP) in CHO-based biotherapeutics. This kit employs avian immunoglobulin Y (IgY) antibodies derived from specific pathogen-free (SPF) chicken eggs, achieving enhanced sensitivity and specificity with detection limits as low as 0.1 ng/mL and 90% antibody coverage. This innovation aims to enhance quality control in biopharmaceutical development, ensuring the safety and efficacy of new therapies while offering flexibility for client use, either independently or with support from Charles River’s experts.

In February 2024, Dyadic International Inc., a biotechnology company based in the US, formed a partnership with Cygnus Technologies to provide a C1 host cell protein (HCP) enzyme-linked immunosorbent assay designed to enhance quality assurance in biomanufacturing. This collaboration centers on quantifying host cell proteins derived from Dyadic's proprietary C1 cells, which utilize the filamentous fungus Thermothelomyces heterothallica. Cygnus Technologies LLC is also a biopharmaceutical company based in the US.

Major companies operating in the enzyme-linked immunosorbent assay testing market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Tecan Group Ltd., GenScript Biotech Corporation, Promega Corporation, Abcam plc, R&D Systems Inc, Sino Biological Inc., OriGene Technologies Inc., RayBiotech Inc., Santa Cruz Biotechnology Inc., AnaSpec Inc., Biomatik, Arigo Biolaboratories Corp., MyBioSource Inc., Boster Biological Technology, Eagle Biosciences Inc., Enzo Life Sciences Inc., StressMarq Biosciences Inc., XpressBio.

North America was the largest region in the enzyme-linked immunosorbent assay testing market in 2023. The regions covered in the enzyme-linked immunosorbent assay testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the enzyme-linked immunosorbent assay testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Enzyme-linked immunosorbent assay (ELISA) testing is a widely used laboratory technique designed to detect and quantify specific proteins, antigens, or antibodies in a sample. The method involves immobilizing an antigen or antibody on a solid surface, typically a microplate, and then using enzyme-linked antibodies or antigens to bind to the target molecule.

The main types of ELISA testing include direct enzyme-linked immunosorbent assay (ELISA), sandwich enzyme-linked immunosorbent assay (ELISA), indirect enzyme-linked immunosorbent assay (ELISA), multiple and portable enzyme-linked immunosorbent assays (ELISA), and competitive enzyme-linked immunosorbent assays (ELISA). Direct enzyme-linked immunosorbent assay (ELISA) involves directly immobilizing an antigen on a solid surface. This method can be used for applications in immunology, inflammation, infectious diseases, cancer, protein quantitation, and other areas, serving various end users such as hospitals and diagnostic centers, research laboratories, and more.

The enzyme-linked immunosorbent assay testing market research report is one of a series of new reports that provides enzyme-linked immunosorbent assay testing market statistics, including enzyme-linked immunosorbent assay testing industry global market size, regional shares, competitors with an enzyme-linked immunosorbent assay testing market share, detailed enzyme-linked immunosorbent assay testing market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme-linked immunosorbent assay testing industry. This enzyme-linked immunosorbent assay testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The enzyme-linked immunosorbent assay testing market consists of revenues earned by entities providing services such as diagnostic testing, research and development, detection of antibodies, and vaccine development. The market value includes the value of related goods sold by the service provider or included within the service offering. The enzyme-linked immunosorbent assay testing market also includes sales of ELISA kits, control samples, inhibitor assays, and other consumables such as microplate readers, washers, and automated ELISA systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.